Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer

Experimental Neurology

Volumn 177, Issue 2, 2002, Pages 461-474

  Georgievska, Biljana ^a   Kirik, Deniz ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Behavior; Parkinson's disease; Sprouting; Stereology

Indexed keywords

AMPHETAMINE; DOPAMINE; FLUOROGOLD; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; NEUROTROPHIC FACTOR; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL ASSAY; CELL LABELING; CELL LINE; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DENSITY; FEMALE; FIBER; GENE TRANSFER; GLIA CELL; IMMUNOHISTOCHEMISTRY; LOCOMOTION; NERVE CELL; NERVE CELL LESION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROTATION; STRUCTURE ANALYSIS; SYNTHESIS; TIME;

EID: 0036434879     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.8006     Document Type: Article

References (42)

1. Bensadoun, J. C., N. Déglon, J. L. Tseng, J. L. Ridet, A. D. Zurn, and P. Aebischer. 2000. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol 164: 15-24.
2. Bilang-Bleuel, A., F. Revah, P. Colin, I. Locquet, J. J. Robert, J. Mallet, and P. Horellou. 1997. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 94: 8818-8823.
3. Björklund, A., C. Rosenblad, C. Winkler, and D. Kirik. 1997. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4: 186-200.
4. Björklund, A., D. Kirik, C. Rosenblad, B. Georgievska, C. Lund-berg, and R. J. Mandel. 2000. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886: 82-98.
5. Björklund, A., and O. Lindvall. 2000. Parkinson disease gene therapy moves toward the clinic. Nat. Med. 6: 1207-1208.
6. Bowenkamp, K. E., A. F. Hoffman, G. A. Gerhardt, M. A. Henry, P. T. Biddle, B. J. Hoffer, and A. C. Granholm. 1995. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355: 479-489.
7. Choi-Lundberg, D. L., Q. Lin, T. Schallert, D. Crippens, B. L. Davidson, Y. N. Chang, Y. L. Chiang, J. Qian, L. Bardwaj, and M. C. Bohn. 1998. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154: 261-275.
8. Connor, B., D. A. Kozlowski, T. Schallert, J. L. Tillerson, B. L. Davidson, and M. C. Bohn. 1999. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6: 1936-1951.
9. Conway, J. E., S. Zolotukhin, N. Muzyczka, G. S. Hayward, and B. J. Byrne. 1997. Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J. Virol. 71: 8780-8789.
10. Déglon, N., J. L. Tseng, J. C. Bensadoun, A. D. Zurn, Y. Arsenijevic, L. Pereira de Almeida, R. Zufferey, D. Trono, and P. Aebischer. 2000. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11: 179-190.
11. Gash, D. M., Z. Zhang, and G. Gerhardt. 1998. Neuroprotective and neurorestorative properties of GDNF. Ann. Neurol. 44: S121-S125.
12. Georgievska, B., D. Kirik, C. Rosenblad, C. Lundberg, and A. Björklund. 2002. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13: 75-82.
13. Hebert, M. A., and G. A. Gerhardt. 1997. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J. Pharmacol. Exp. Ther. 282: 760-768.
14. Horger, B. A., M. C. Nishimura, M. P. Armanini, L. C. Wang, K. T. Poulsen, C. Rosenblad, D. Kirik, B. Moffat, L. Simmons, E. Johnson, Jr., J. Milbrandt, A. Rosenthal, A. Bjorklund, R. A. Vandlen, M. A. Hynes, and H. S. Phillips. 1998. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18: 4929-4937.
15. Hudson, J., A. C. Granholm, G. A. Gerhardt, M. A. Henry, A. Hoffman, P. Biddle, N. S. Leela, L. Mackerlova, J. D. Lile, F. Collins, et al. 1995. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res. Bull. 36: 425-432.
16. Kirik, D., C. Rosenblad, and A. Björklund. 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152: 259-277.
17. Kirik, D., C. Rosenblad, and A. Björklund. 2000. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur. J. Neurosci. 12: 3871-3882.
18. Kirik, D., C. Rosenblad, A. Björklund, and R. J. Mandel. 2000. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20: 4686-4700.
19. Kirik, D., B. Georgievska, C. Rosenblad, and A. Björklund. 2001. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci. 13: 1589-1599.
20. Kirik, D., C. Winkler, and A. Björklund. 2001. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 21: 2889-2896.
21. Kordower, J. H., M. E. Emborg, J. Bloch, S. Y. Ma, Y. Chu, L. Leventhal, J. McBride, E. Y. Chen, S. Palfi, B. Z. Roitberg, W. D. Brown, J. E. Holden, R. Pyzalski, M. D. Taylor, P. Carvey, Z. Ling, D. Trono, P. Hantraye, N. Déglon, and P. Aebischer. 2000. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767-773.
22. Kozlowski, D. A., B. Connor, J. L. Tillerson, T. Schallert, and M. C. Bohn. 2000. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. 166: 1-15.
23. Lapchak, P. A., D. M. Gash, S. Jiao, P. J. Miller, and D. Hilt. 1997. Glial cell line-derived neurotrophic factor: A novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp. Neurol. 144: 29-34.
24. Lapchak, P. A., P. J. Miller, and S. Jiao. 1997. Glial cell line-derived neurotrophic factor induces the dopaminergic and cho-linergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience 77: 745-752.
25. Martin, D., G. Miller, T. Cullen, N. Fischer, D. Dix, and D. Russell. 1996. Intranigral or intrastriatal injections of GDNF: Effects on monoamine levels and behavior in rats. Eur. J. Pharmacol. 317: 247-256.
26. Martin, D., G. Miller, N. Fischer, D. Diz, T. Cullen, and D. Russell. 1996. Glial cell line-derived neurotrophic factor: The lateral cerebral ventricle as a site of administration for stimulation of the substantia nigra dopamine system in rats. Eur. J. Neurosci. 8: 1249-1255.
27. McLaughlin, S. K., P. Collis, P. L. Hermonat, and N. Muzyczka. 1988. Adeno-associated virus general transduction vectors: Analysis of proviral structures. J. Virol. 62: 1963-1973.
28. Montoya, C. P., L. J. Campbell-Hope, K. D. Pemberton, and S. B. Dunnett. 1991. The "staircase test": A measure of independent forelimb reaching and grasping abilities in rats. J. Neurosci. Methods 36: 219-228.
29. Olsson, M., G. Nikkhah, C. Bentlage, and A. Bjöklund. 1995. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15: 3863-3875.
30. Paxinos, G., and C. Watson. 1998. The Rat Brain in Stereotaxic Coordinates, 4th Ed. Academic Press, San Diego.
31. Rosenblad, C., A. Martinez-Serrano, and A. Bjorklund. 1998. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82: 129-137.
32. Rosenblad, C., D. Kirik, B. Devaux, B. Moffat, H. S. Phillips, and A. Bjorklund. 1999. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur. J. Neurosci. 11: 1554-1566.
33. Rosenblad, C., M. Grønborg, C. Hansen, N. Blom, M. Meyer, J. Johansen, L. Dagø, D. Kirik, U. A. Patel, C. Lundberg, D. Trono, A. Björklund, and T. E. Johansen. 2000. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Mol. Cell. Neurosci. 15: 199-214.
34. Rosenblad, C., D. Kirik, and A. Bjöklund. 2000. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol. 161: 503-516.
35. Schallert, T., D. A. Kozlowski, J. L. Humm, and R. R. Cocke. 1997. Use-dependent structural events in recovery of function. Adv. Neurol. 73: 229-238.
36. Tseng, J. L., E. E. Baetge, A. D. Zurn, and P. Aebischer. 1997. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17: 325-333.
37. Ungerstedt, U., and G. W. Arbuthnott. 1970. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24: 485-493.
38. von Schwedler, U., J. Song, C. Aiken, and D. Trono. 1993. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67: 4945-4955.
39. West, M. J. 1999. Stereological methods for estimating the total number of neurons and synapses: Issues of precision and bias. Trends Neurosci. 22: 51-61.
40. Winkler, C., H. Sauer, C. S. Lee, and A. Björklund. 1996. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16: 7206-7215.
41. Zolotukhin, S., B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter, K. Chesnut, C. Summerford, R. J. Samulski, and N. Muzyczka. 1999. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6: 973-985.
42. Zufferey, R., D. Nagy, R. J. Mandel, L. Naldini, and D. Trono. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15: 871-875.